Top

Breast Cancer Research and Treatment

Published in:

01-08-2018 | Letter to the Editor

Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy

Authors: Francesca Poggio, Benedetta Conte, Matteo Lambertini

Published in: Breast Cancer Research and Treatment | Issue 1/2018

Excerpt

To the Editor, …

Zhang Y, Ji Y, Li J et al (2018) Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival. Breast Cancer Res Treat 168:679–686. https://doi.org/10.1007/s10549-018-4660-y CrossRefPubMed

Regan MM, Walley BA, Francis PA et al (2017) Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 28:2225–2232. https://doi.org/10.1093/annonc/mdx285 CrossRefPubMedPubMedCentral

Lambertini M, Moore HCF, Leonard RCF et al (2018) Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol. https://doi.org/10.1200/JCO.2018.78.0858 PubMedCrossRef

Oktay K, Harvey BE, Partridge AH et al (2018) Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. https://doi.org/10.1200/JCO.2018.78.1914 PubMedCrossRef

Paluch-Shimon S, Pagani O, Partridge AH et al (2017) ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast 35:203–217. https://doi.org/10.1016/j.breast.2017.07.017 CrossRefPubMed

Lambertini M, Cinquini M, Moschetti I et al (2017) Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. Eur J Cancer 71:25–33. https://doi.org/10.1016/j.ejca.2016.10.034 CrossRefPubMed

Title: Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy
Authors: Francesca Poggio
Benedetta Conte
Matteo Lambertini
Publication date: 01-08-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4806-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2018

SNP rs2071095 in LincRNA H19 is associated with breast cancer risk

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial

Predictors of surveillance mammography outcomes in women with a personal history of breast cancer

Genetic dissection of the BRCA2 promoter and transcriptional impact of DNA variants

Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists

Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer